West Pharmaceutical Services, Inc. (WST) 當前追蹤本益比 (P/E) 為 38.3, 前瞻本益比為 33.4. 追蹤盈利收益率為 2.61%, 前瞻盈利收益率 2.99%. PEG 23.92. 葛拉漢數為 $82.15.
本頁證實的標準:
SharesGrow 綜合評分： 66/100 其中 4/7 項標準通過。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 43.3 | 0.91 | 5.56 | 4.12 | 0.58% |
| 2017 | 48.4 | 11.85 | 5.70 | 4.56 | 0.54% |
| 2018 | 35.0 | 0.94 | 5.19 | 4.22 | 0.58% |
| 2019 | 46.0 | 2.74 | 7.07 | 6.03 | 0.41% |
| 2020 | 60.5 | 1.40 | 11.29 | 9.75 | 0.23% |
| 2021 | 52.7 | 0.58 | 14.94 | 12.33 | 0.15% |
| 2022 | 29.9 | -2.61 | 6.52 | 6.07 | 0.31% |
| 2023 | 44.1 | 31.58 | 9.08 | 8.87 | 0.22% |
| 2024 | 48.5 | -3.13 | 8.91 | 8.27 | 0.25% |
| 2025 | 40.3 | 34.00 | 6.26 | 6.47 | 0.31% |
| Year | EPS（稀釋） | 營收 | 淨利潤 | 淨利潤率 |
|---|---|---|---|---|
| 2016 | $1.91 | $1.51B | $143.6M | 9.5% |
| 2017 | $1.99 | $1.6B | $150.7M | 9.4% |
| 2018 | $2.74 | $1.72B | $206.9M | 12% |
| 2019 | $3.21 | $1.84B | $241.7M | 13.1% |
| 2020 | $4.57 | $2.15B | $346.2M | 16.1% |
| 2021 | $8.67 | $2.83B | $661.8M | 23.4% |
| 2022 | $7.73 | $2.89B | $585.9M | 20.3% |
| 2023 | $7.88 | $2.95B | $593.4M | 20.1% |
| 2024 | $6.69 | $2.89B | $492.7M | 17% |
| 2025 | $6.80 | $3.07B | $493.7M | 16.1% |
| Year | EPS（平均） | EPS 範圍 | 營收（平均） | 營收範圍 | 分析師人數 |
|---|---|---|---|---|---|
| 2026 | $8.03 | $7.49 – $8.19 | $3.25B | $3.23B – $3.27B | 9 |
| 2027 | $8.88 | $8.51 – $9.12 | $3.45B | $3.43B – $3.48B | 9 |
| 2028 | $10.18 | $9.61 – $10.75 | $3.7B | $3.69B – $3.7B | 2 |
| 2029 | $11.11 | $10.95 – $11.26 | $3.93B | $3.89B – $3.97B | 1 |
| 2030 | $11.36 | $11.19 – $11.51 | $4.03B | $3.98B – $4.07B | 1 |
